Risk/benefit assessment of tamoxifen to prevent breast cancer-still a work in progress?
Taylor
A L
AL
Adams-Campbell
L L
LL
Wright
J T
JT
D001741:Black or African American / Q000706:statistics & numerical data; D016588:Anticarcinogenic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000208:ethnology / Q000517:prevention & control*; D016889:Endometrial Neoplasms / Q000139:chemically induced; D020847:Estrogen Receptor Modulators / Q000009:adverse effects*; D005260:Female; D006801:Humans; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects*; D020521:Stroke / Q000139:chemically induced; D013629:Tamoxifen / Q000009:adverse effects*; D020246:Venous Thrombosis / Q000139:chemically induced; D044465:White People / Q000706:statistics & numerical data
D016588:Anticarcinogenic Agents; D020847:Estrogen Receptor Modulators; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen